24698-43-9

Basic information

• Product Name: BENZENESULPHONICACIDISOBUTYLESTER
• Synonyms: BENZENESULPHONICACIDISOBUTYLESTER;Benzenesulfonic acid isobutyl ester;Benzenesulfonic acid, isobutyl ester;Ccris 9152;Benzenesulfonic acid, 2-Methylpropyl ester
• CAS NO: 24698-43-9
• Molecular Formula: C₁₀H₁₄O₃S
• Molecular Weight: 214.28
• Mol File: 24698-43-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 291.726°C at 760 mmHg
• Flash Point: 130.232°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.511
• CAS DataBase Reference: BENZENESULPHONICACIDISOBUTYLESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENESULPHONICACIDISOBUTYLESTER(24698-43-9)
• EPA Substance Registry System: BENZENESULPHONICACIDISOBUTYLESTER(24698-43-9)

Safety Data

• Hazardous Substances Data: 24698-43-9(Hazardous Substances Data)

Usage

Description

BENZENESULPHONICACIDISOBUTYLESTER, also known as Isobutyl Benzenesulfonate, is an organic compound that serves as an intermediate in the synthesis of Febuxostat (F229000). It is characterized by its chemical structure, which includes a benzene ring with a sulfonate group and an isobutyl ester. BENZENESULPHONICACIDISOBUTYLESTER plays a crucial role in the pharmaceutical industry due to its involvement in the production of a medication used for treating specific medical conditions.

Uses

Used in Pharmaceutical Industry:
BENZENESULPHONICACIDISOBUTYLESTER is used as an intermediate for the synthesis of Febuxostat (F229000) for its role in the treatment of hyperuricemia and chronic gout. Febuxostat is an xanthine oxidase/xanthine dehydrogenase inhibitor, which helps in lowering serum urate levels, thus providing relief from the symptoms of gout and hyperuricemia.
Application Reason:
The use of BENZENESULPHONICACIDISOBUTYLESTER in the pharmaceutical industry is primarily due to its ability to act as a key intermediate in the production of Febuxostat. This medication has been proven effective in managing hyperuricemia in patients with gout when administered at a dosage of 40-120 mg/day. By inhibiting the xanthine oxidase/xanthine dehydrogenase enzyme, Febuxostat reduces the production of uric acid, thereby alleviating the symptoms associated with gout and hyperuricemia.

InChI:InChI=1/C9H12O3S/c1-8(2)12-13(10,11)9-6-4-3-5-7-9/h3-8H,1-2H3

Upstream product

• 934534-79-9 iso-butyl 2-bromobenzenesulfonate 
• 1083004-75-4 (S)-N₁-(2,6-diethylphenyl)-2-phenylethane-1,2-diamine 
• 78-83-1 2-methyl-propan-1-ol 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 161798-03-4 2-(3-formyl-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 
• 44976-81-0 N,N-bis(1-methylethyl)-2-methyl-1-propanamine 
• 766552-33-4 2-isobutoxy-4-nitrobenzoic acid 

Relevant articles and documents

New preparation method of febuxostat intermediate

The invention relates to a new preparation method of a febuxostat intermediate. The method includes: taking cheap 4-hydroxybenzaldehyde as an initial raw material, firstly preparing aldoxime from 4-hydroxybenzaldehyde and hydroxylamine hydrochloride, then adding a corresponding thio reagent, and preparing a compound 4-hydroxythiobenzamide (152A1-00) by Beckmann rearrangement reaction; utilizing one-pot process, adopting cheap 4-hydroxybenzaldehyde as an initial raw material, carrying out a series of reactions, and then performing cyclization with 2-halogenated ethyl acetoacetate to obtain ethyl 2-(4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate or different salt forms (152A2x) thereof; and using isobutyl sulfonate (152H1x) with more easily controllable quality to replace bromo-isobutane soas to prepare ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate (152A4-00). In conclusion, the method provided by the invention is more beneficial to safe, simple and cost-efficientindustrial scale preparation of the febuxostat intermediate with higher purity.